Voyager Therapeutics, Inc. (VYGR)

Market Cap	107.22M -59.5%
Revenue (ttm)	34.46M -19.1%
Net Income	-107.73M
EPS	-1.81
Shares Out	61.62M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,052,312
Open	1.820
Previous Close	1.860
Day's Range	1.740 - 1.840
52-Week Range	1.740 - 5.478
Beta	1.28
Analysts	Strong Buy
Price Target	14.89 (+755.75%)
Est. Earnings	Nov 9, 2026

About VYGR

Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer’s disease. The company also provides research program for the treatment of Huntington’s disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small mo...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 11, 2015
• Employees: 141
• Stock Exchange: Nasdaq
• Ticker Symbol: VYGR
• Website: https://www.voyagertherapeutics.com

Financial Performance

In 2025, Voyager Therapeutics's revenue was $40.37 million, a decrease of -49.53% compared to the previous year's $80.00 million. Losses were -$119.72 million, 84.2% more than in 2024.

Analyst Summary

According to 11 analysts, the average rating for VYGR stock is "Strong Buy." The 12-month stock price target is $14.89, which is an increase of 755.75% from the latest price.

Price Target

$14.89

(755.75% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 24, 2026

Data Sources Report a data error